Figure 3From: The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthmaEarly and late asthmatic response to inhaled allergen challenge after 7 days treatment with either GSK256066 or placebo. Means and 95% confidence intervals of change in FEV1 compared to post saline value shown.Back to article page